Statins and osteoporosis: new role for old drugs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Adami, 2001, Association between bone mineral density and serum lipids in men, JAMA, 286, 791, 10.1001/jama.286.7.791
Banu, 2002, Effects of cerivastatin and parathyroid hormone on the lumbar vertebra of aging male Sprague-Dawley rats, Bone, 31, 173, 10.1016/S8756-3282(02)00803-7
Bauer, 2003, HMG-CoA reductase inhibitors and the skeleton: a comprehensive review, Osteoporos. Int., 14, 273, 10.1007/s00198-002-1323-x
Bauer, 1999, Statin use, bone mass and fracture: an analysis of two prospective studies, J. Bone Miner. Res., 14, 1188
Bauer, 2004, Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials, Arch. Intern. Med., 164, 146, 10.1001/archinte.164.2.146
Baumann, 2001, Inhibition of osteoclast formation by statins, J. Bone Miner. Res., 16, S507
Baylink, 1999, The diagnosis and treatment of osteoporosis: future prospects, Mol. Med., 5, 133
Benford, 1999, Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs, Mol. Pharmacol., 56, 131, 10.1124/mol.56.1.131
Berthold, 2004, Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women, Osteoporos. Int., 15, 459, 10.1007/s00198-004-1598-1
Bjarnason, 2001, The effect of fluvastatin on parameters of bone remodeling, Osteoporos. Int., 12, 380, 10.1007/s001980170106
Burnett, 2002, Cardiovascular disease and osteoporosis: is there a link between lipids and bone?, Ann. Clin. Biochem., 39, 203, 10.1258/0004563021902134
Canalis, 1989, Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures, J. Clin. Invest., 83, 60, 10.1172/JCI113885
Cauley, 2000, Statin use and bone mineral density (BMD) in older women: the Women's Health Initiative Observational Study (WHI-OS), J. Bone Miner. Res., 15, 1068
Chan, 2000, Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women, Lancet, 355, 2185, 10.1016/S0140-6736(00)02400-4
Chan, 2001, Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia, J. Clin. Endocrinol. Metab., 86, 4556, 10.1210/jcem.86.9.8001
Chung, 2000, HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients, J. Clin. Endocrinol. Metab., 85, 1137
Corsino, 1999, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol. Ther., 84, 413, 10.1016/S0163-7258(99)00045-5
Cosman, 2001, Effects of short-term cerivastatin on bone turnover, J. Bone Miner. Res., 16, S296
Coxon, 2003, The role of prenylated small GTP-binding proteins in the regulation of osteoclast function, Calcif. Tissue Int., 92, 80, 10.1007/s00223-002-2017-2
Crawford, 2001, Statin increases cortical bone in young male rats by single, local administration but fails to restore bone in ovariectomized (OVX) rats by daily systemic administration, J. Bone Miner. Res., 16, S295
De Leo, 2003, Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density, Gynecol. Endocrinol., 17, 329, 10.1080/gye.17.4.329.332
Demer, 2001, Boning up (or down) on statins, Arterioscler. Thromb. Vasc. Biol., 21, 1565, 10.1161/atvb.21.10.1565
Dunford, 2001, Structure-activity relationship for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J. Pharmacol Exp. Ther., 296, 235
Edwards, 2000, Oral statins and increased bone-mineral density in postmenopausal women, Lancet, 355, 2218, 10.1016/S0140-6736(00)02408-9
Fisher, 1999, Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro, Proc. Natl Acad. Sci., 96, 133, 10.1073/pnas.96.1.133
Fogelman, 2005, Strontium ranelate for the treatment of osteoporosis, Br. Med. J., 330, 1400, 10.1136/bmj.330.7505.1400
Frith, 2001, Statins inhibit protein prenylation in osteoclasts in vivo, J. Bone Miner. Res., 16, S507
Fromigue, 2004, Growth factors and bone formation in osteoporosis: roles for fibroblast growth factor and transforming growth factor beta, Curr. Pharm. Design, 10, 2593, 10.2174/1381612043383773
Fujisaki, 1995, Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: Synthesis and in vivo characterization of osteotropic carboxyfluorescein, J. Drug Target., 3, 273, 10.3109/10611869509015956
Fujisaki, 1996, Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: Pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein, J. Drug Target., 4, 117, 10.3109/10611869609046270
Fujisaki, 1997, Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. V: Biological disposition and targeting characteristics of osteotropic estradiol, Biol. Pharm. Bull., 20, 1183, 10.1248/bpb.20.1183
Fujisaki, 1998, Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. IV: Effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats, J. Drug Target., 5, 129, 10.3109/10611869808995866
Funkhouser, 2002, Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density, J. Clin. Densitom., 5, 151, 10.1385/JCD:5:2:151
Furberg, 2002, Withdrawal of cerivastatin from the world market, Curr. Control. Trials Cardiovasc. Med., 2, 205
Garrett, 2000, Statins mediate their effects on osteoblasts by inhibition of HMG-CoA reductase and ultimately BMP-2, J. Bone Miner. Res., 15, S225
Garrett, 2001, Statins stimulate bone formation by enhancing eNOS expression, J. Bone Miner. Res., 16, S141
Gasser, 2001, Fluvastatin and cerivastatin are not anabolic for bone after local or systemic administration of nontoxic doses in mice and rats, J. Bone Miner. Res., 16, S295
Gonyeau, 2005, Statins and osteoporosis: a clinical review, Pharmacotherapy, 25, 228, 10.1592/phco.25.2.228.56954
Gutierrez, 2000, Dermal application of lovastatin to rats causes greater increases in bone formation and plasma concentrations than when administered by oral gavage, J. Bone Miner. Res., 15, S427
Gutierrez, 2001, Dermal application of lovastatin for 5 days stimulates bone formation in ovariectomized rats by 160%, J. Bone Miner. Res., 16, S222
Hamerman, 2005, Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies, Q. J. Med., 98, 467, 10.1093/qjmed/hci077
Harris, 1994, Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells, J. Bone Miner. Res., 9, 389, 10.1002/jbmr.5650090314
Hatzigeorgiou, 2005, Hydroxymethylglutarylcoenzyme A reductase inhibitors and osteoporosis: a metaanalysis, Osteoporos. Int., 16, 990, 10.1007/s00198-004-1793-0
Hirabayashi, 2001, Bone specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the osteotropic drug delivery system (ODDS), J. Control. Release, 70, 183, 10.1016/S0168-3659(00)00355-2
Hoffmann, 2001, BMP signaling pathways in cartilage and bone formation, Crit. Rev. Eur. Gene Expr., 11, 23
Hsia, 2002, Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose ranging trial, BMC Musculoskelet. Disord., 3, 1, 10.1186/1471-2474-3-7
Hwang, 2004, Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone, J. Biol. Chem., 279, 21239, 10.1074/jbc.M312771200
Izumo, 2001, Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner, Methods Find. Exp. Clin. Pharmacol., 23, 389, 10.1358/mf.2001.23.7.662123
Jiang, 2001, Effect of simvastatin on three-dimensional trabecular architecture of ovariectomized rats, J. Bone Miner. Res., 16, S296
Kanis, 2000, Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis, Bone, 27, 585, 10.1016/S8756-3282(00)00381-1
Karsenty, 2000, Role of cbfa1 in osteoblast differentiation and function, Semin. Cell Dev. Biol., 11, 343, 10.1006/scdb.2000.0188
Komori, 2000, A fundamental transcription factor for bone and cartilage, Biochem. Biophys. Res. Commun., 276, 813, 10.1006/bbrc.2000.3460
Kugimiya, 2005, Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP 6 in bone formation, J. Biol. Chem., 280, 35704, 10.1074/jbc.M505166200
Kurland, 2000, Therapy of idiopathic osteoporosis in men with parathyroid hormone: effects on bone mineral density and bone markers, J. Clin. Endocrinol. Metab., 85, 3069
LaCroix, 2003, Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study, Ann. Intern. Med., 139, 97, 10.7326/0003-4819-139-2-200307150-00009
Li, 2003, Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures, Bone, 33, 652, 10.1016/S8756-3282(03)00239-4
Lindsay, 1997, Randomized controlled study of the effect of PTH on vertebral bone mass and fracture incidence among post-menopausal women on estrogen with osteoporosis, Lancet, 350, 550, 10.1016/S0140-6736(97)02342-8
Luckman, 1998, Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras, J. Bone Miner. Res., 13, 581, 10.1359/jbmr.1998.13.4.581
Lupattelli, 2004, Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women, Metabolism, 53, 744, 10.1016/j.metabol.2004.01.010
Maeda, 2001, Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells, Biochem. Biophys. Res. Commun., 280, 874, 10.1006/bbrc.2000.4232
Maeda, 2003, Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation, Endocrinology, 144, 681, 10.1210/en.2002-220682
Maeda, 2004, Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells, J. Cell Biochem., 92, 458, 10.1002/jcb.20074
Manolagas, 2000, Birth and death of bone cells: basic regulatory mechanism and implications for the pathogenesis and treatment of osteoporosis, Endocr. Rev., 21, 115
Maritz, 2001, Effect of statins on bone mineral density and bone histomorphometry in rodents, Arterioscler. Thromb. Vasc. Biol., 21, 1636, 10.1161/hq1001.097781
Masarachia, 2001, Effect of statins on bone mass and turnover in ovariectomized rats, J. Bone Miner. Res., 16, S295
Mathews, 2005, Biological activity of bone morphogenetic proteins (BMPs), Injury, 36, S34, 10.1016/j.injury.2005.07.032
McFarlane, 2004, Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?, Endocrine, 23, 1, 10.1385/ENDO:23:1:01
Meier, 2000, HMG-CoA reductase inhibitors and the risk of fractures, JAMA, 283, 3205, 10.1001/jama.283.24.3205
Meunier, 2001, Anabolic agents for treating postmenopausal osteoporosis, Joint Bone Spine, 68, 576, 10.1016/S1297-319X(01)00329-3
Meunier, 1998, Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOS study, Osteoporos. Int., 8, 4, 10.1007/s001980050041
Meunier, 2004, The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis, N. Engl. J. Med., 350, 459, 10.1056/NEJMoa022436
Montagnani, 2003, Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study, Bone, 32, 427, 10.1016/S8756-3282(03)00034-6
Mostaza, 2001, Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women, Clin. Chim. Acta., 308, 133, 10.1016/S0009-8981(01)00476-4
Mundy, 2001, Statins and their potential for osteoporosis, Bone, 29, 495, 10.1016/S8756-3282(01)00606-8
Mundy, 1999, Stimulation of bone formation in vitro and in rodents by statins, Science, 286, 1946, 10.1126/science.286.5446.1946
National Osteoporosis Foundation, 2005, Fast facts on osteoporosis
Neer, 2001, Effect of parathyroid hormone (1–34) on fracture and bone mineral density in postmenopausal women with osteoporosis, N. Engl. J. Med., 344, 1434, 10.1056/NEJM200105103441904
Nuttal, 2000, Is there any opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?, Bone, 27, 177, 10.1016/S8756-3282(00)00317-3
Ohnaka, 2001, Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts, Biochem. Biophys. Res. Commun., 287, 337, 10.1006/bbrc.2001.5597
Ohno, 2003, Skeletal reconstruction by vascularized allogenic bone transplantation: effects of statin in rats, Transplantation, 76, 869, 10.1097/01.TP.0000074992.49236.58
Oxlund, 2004, Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation, Bone, 34, 609, 10.1016/j.bone.2003.12.014
Oxlund, 2001, Statin given per orally to adult rats increases cancellous bone mass and compressive strength, Calcif. Tissue Int., 69, 299, 10.1007/s00223-001-2027-5
Pak, 1995, Treatment of postmenopausal osteoporosis with slow-release NaF, Ann. Intern. Med., 123, 401, 10.7326/0003-4819-123-6-199509150-00001
Parhami, 1997, Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients, Arterioscler. Thromb. Vasc. Biol., 17, 680, 10.1161/01.ATV.17.4.680
Parhami, 2000, Role of lipids in osteoporosis, Arterioscler. Thromb. Vasc. Biol., 20, 2346, 10.1161/01.ATV.20.11.2346
Parhami, 2001, Atherogenic high fat diet reduces bone mineralization in mice, J. Bone Miner. Res., 16, 182, 10.1359/jbmr.2001.16.1.182
Parhami, 2002, Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells, J. Bone Miner. Res., 17, 1997, 10.1359/jbmr.2002.17.11.1997
Pasco, 2002, Geelong Osteoporosis Study. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study, Arch. Intern. Med., 162, 537, 10.1001/archinte.162.5.537
Pedersen, 2000, Statin drugs and the risk of fracture, JAMA, 284, 1921
Pedersen, 1996, Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study, Arch. Intern. Med., 156, 2085, 10.1001/archinte.1996.00440170097011
Pedersen, 2004, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 1994, Atheroscler., 5, 81, 10.1016/j.atherosclerosissup.2004.08.027
Phillips, 2001, Compactin enhances osteogenesis in murine embryonic stem cells, Biochem. Biophys. Res. Commun., 284, 478, 10.1006/bbrc.2001.4987
Ray, 2002, Lipid-lowering agents and the risk of hip fracture in a Medicaid population, Inj. Prev., 8, 276, 10.1136/ip.8.4.276
Reeve, 1980, Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicenter trial, Br. Med. J., 280, 1340, 10.1136/bmj.280.6228.1340
Reginster, 1998, The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized controlled trial, Ann. Intern. Med., 129, 1, 10.7326/0003-4819-129-1-199807010-00001
Reginster, 2005, Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study, J. Clin. Endocrinol. Metab., 90, 2816, 10.1210/jc.2004-1774
Reid, 2001, Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Long-term Intervention with Pravastatin in Ischemic Disease, Lancet, 357, 509, 10.1016/S0140-6736(00)04042-3
Reinoso, 2002, Preclinical pharmacokinetics of statins, Methods Fin. Clin. Pharmacol., 24, 593, 10.1358/mf.2002.24.9.802312
Rejnmark, 2002, Statins decrease bone turnover in postmenopausal women: a cross-sectional study, Eur. J. Clin. Invest., 32, 581, 10.1046/j.1365-2362.2002.01024.x
Rejnmark, 2004, Hip fracture risk in statin users—a population-based Danish case—control study, Osteoporos. Int., 15, 452, 10.1007/s00198-003-1568-z
Rejnmark, 2004, Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women, J. Bone Miner. Res., 19, 737, 10.1359/jbmr.040209
Rickard, 1994, Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2, Dev. Biol., 161, 218, 10.1006/dbio.1994.1022
Riggs, 1982, Effect of fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy, N. Engl. J. Med., 306, 446, 10.1056/NEJM198202253060802
Riggs, 1990, Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis, N. Engl. J. Med., 322, 802, 10.1056/NEJM199003223221203
Rittermaster, 2000, Enhancement of bone mass in osteoporotic women with PTH followed by alendronate, J. Clin. Endocrinol. Metab., 85, 2129
Rosen, 2001, Clinical review 123: hot topic anabolic therapy for osteoporosis, J. Clin. Endocrinol. Metab., 86, 957, 10.1210/jcem.86.3.7366
Salbach, 2001, Short-term treatment with atorvastatin does not change bone turnover in hypercholesterolemia: a randomized controlled study, J. Bone Miner. Res., 16, S295
Sato, 2001, The skeletal efficacy of statins do not compare with low dose parathyroid hormone, Bone, 28, S80
Schoofs, 2004, HMG-CoA reductase inhibitors and the risk of vertebral fracture, J. Bone Miner. Res., 19, 1525, 10.1359/JBMR.040607
Sirola, 2002, Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women, Osteoporos. Int., 13, 537, 10.1007/s001980200070
Skoglund, 2002, Simvastatin improves fracture healing in mice, J. Bone Miner. Res., 17, 2004, 10.1359/jbmr.2002.17.11.2004
Solomon, 2001, Statin lipid- lowering drugs and bone density, J. Bone Miner. Res., 16, S293
Song, 2003, Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells, Biochem. Biophys. Res. Commun., 308, 458, 10.1016/S0006-291X(03)01408-6
Staal, 2003, The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity, J. Bone Miner. Res., 18, 88, 10.1359/jbmr.2003.18.1.88
Stein, 2001, Effects of statins on biomarkers of bone metabolism: a randomized trial, Nutr. Metab. Cardiovasc. Dis., 11, 84
Sugiyama, 2000, Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells, Biochem. Biophys. Res. Commun., 271, 688, 10.1006/bbrc.2000.2697
Tanriverdi, 2005, Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women, Eur. J. Obstet. Gynecol. Reprod. Biol., 120, 63, 10.1016/j.ejogrb.2004.08.007
Thylin, 2002, Effects of simvastatin gels on murine calvarial bone, J. Periodontol., 73, 1141, 10.1902/jop.2002.73.10.1141
Van Beek, 1999, The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen containing bisphosphonates, J. Bone Miner. Res., 14, 722, 10.1359/jbmr.1999.14.5.722
Von Stechow, 2003, Does simvastatin stimulate bone formation in vivo?, BMC Musculoskelet. Disord., 4, 8, 10.1186/1471-2474-4-8
Wada, 2000, Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes, Arch. Intern. Med., 160, 2865, 10.1001/archinte.160.18.2865
Wang, 1995, Lipid clearing agents in steroid-induced osteoporosis, J. Formos. Med. Assoc., 94, 589
Wang, 2000, HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients, JAMA, 283, 3211, 10.1001/jama.283.24.3211
Wang, 2003, Mechanism of simvastatin on induction of heat shock protein in osteoblasts, Arch. Biochem. Biophys., 415, 6, 10.1016/S0003-9861(03)00213-3
Watanabe, 2000, Effects of one year treatment with statins on bone mass and metabolism, J. Bone Miner. Res., 15, S194
Whang, 2000, Administration of lovastatin locally in low doses in a novel delivery system induces prolonged bone formation, J. Bone Miner. Res., 15, S225
Whang, 2005, A novel osteotropic biomaterial OG-PLG: synthesis and in vitro release, J. Biomed. Mater. Res. A., 74, 237, 10.1002/jbm.a.30309
Wilkie, 2000, Cerivastatin increases cortical bone formation in OVX rats, J. Bone Miner. Res., 15, S549
William, 2002, Pharmacokinetic-pharmacodynamic drug interaction with HMG-CoA reductase inhibitors, Clin. Pharmacokinet., 41, 343, 10.2165/00003088-200241050-00003
Xiao, 2002, Bone morphogenetic proteins, extracellular matrix, mitogen-activated protein kinases signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells, J. Bone Miner. Res., 17, 101, 10.1359/jbmr.2002.17.1.101
Yao, 2001, Simvastatin did not prevent bone loss in ovariectomized rats, J. Bone Miner. Res., 16, S294
Yataru, 2001, Statins and bone mineral density, J. Bone Miner. Res., 16, S294